Vidutolimod

DB17500InvestigationalNucleic Acid Based Therapies

Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.

Mechanism
Curator reviewed
Also known as
Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist · Dna, d(g-g-g-g-g-g-g-g-g-g-g-a-c-g-a-t-c-g-t-c-g-g-g-g-g-g-g-g-g-g)
Code names
ARB-1598 · CMP-001 · CYT-003 · QbG10

Resolves to

Compound
UNIID68OW5RS98CAS147063-80-7
Targets
Q9NR96TLR9Q8WTT0CLEC4C

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
24Clinical trialsPhase, status and sponsor resolved per trial
Sign in
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Vidutolimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In